Newswire (Published: Tuesday, March 7, 2017, Received: Thursday, March 2, 2017, 2:00:58 PM CST)

Word Count: 439

Study Findings from A. Gomez-Iturriaga et al Broaden Understanding of Prostate Cancer (Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision)

By a News Reporter-Staff News Editor at Cancer Weekly -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting originating from Baracaldo, Spain, by NewsRx correspondents, research stated, "Multiparametric MRI (mpMRI) has a potential role for the identification of aggressive cancer that can be targeted for biopsy. We report the incidence and severity of discordant information between the pathology found on the transrectal ultrasound (TRUS) guided biopsy and the mpMRI findings in patients with favorable or intermediate-risk prostate cancer referred for brachytherapy."

Our news editors obtained a quote from the research, "From March-2014 to September 2015, 10/44 consecutive patients with low- or intermediate-risk prostate cancer referred for brachytherapy presented an aggressive lesion on mpMRI and underwent an MRI-TRUS fusion-guided transperineal biopsy of the index lesion. A median of two intraprostatic lesions were detected by mpMRI for each patient. Three patients had bilateral disease, and seven had unilateral disease on mpMRI. The median number of cores obtained by MRI-TRUS guided fusion of the index lesion was 3 (range 2-4). As a result of the re-evaluation consequent to additional information becoming available after the transperineal biopsy, upgrading of Gleason score occurred in 8 of the 10 patients, which changed the risk group in 9 patients. These changes resulted in modification of the proposed treatment in 8 patients."

According to the news editors, the research concluded: "MpMRI-US fusion-targeted biopsy sampling allows detection and characterization of otherwise undetected aggressive disease, often placing men in higher risk groups and altering the treatment approach."

For more information on this research see: Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision. Brachytherapy, 2017;16(1):201-206. Brachytherapy can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier -; Brachytherapy -

The news editors report that additional information may be obtained by contacting A. Gomez-Iturriaga, Hosp Univ Cruces, Biocruces Hlth Res Inst, Radiat Oncol, Baracaldo, Spain. Additional authors for this research include F. Casquero, J.I. Lopez, A. Urresola, A. Ezquerro, D. Buscher, P. Bilbao and J. Crook (see also Oncology - Prostate Cancer).

Keywords for this news article include: Baracaldo, Spain, Europe, Drugs and Therapies, Prostatic Neoplasms, Prostate Cancer, Brachytherapy, Radiotherapy, Oncology, Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


      Medical Devices
            Medical Treatment Devices
                  Radiosurgery Devices
      Medical Device Manufacturing
            Medical Devices
                  Medical Treatment Devices
                        Radiosurgery Devices


North America
Southern Europe
United States
New York
New York City


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research